Novel molecular pathways in Gorham disease: Implications for treatment
Identifieur interne : 003344 ( Main/Exploration ); précédent : 003343; suivant : 003345Novel molecular pathways in Gorham disease: Implications for treatment
Auteurs : Jeroen Hagendoorn ; Torunn I. Yock ; Inne H. M. Borel Rinkes ; Timothy P. Padera ; David H. EbbSource :
- Pediatric blood & cancer [ 1545-5009 ] ; 2013.
Abstract
Rapid advances in evidence-based treatment schedules are a hallmark of modern oncology. In rare neoplastic diseases, however, clinical expertise is hard to build and evidence based on randomized trials almost impossible to conduct. Gorham disease is a rare form of lymphatic proliferation accompanied by osteolysis, which usually occurs in young adults. Despite the fact that the clinical course of Gorham disease is often devastating and occasionally fatal, insights into its biological background are sparse and standardized treatment unavailable. Interestingly, recent knowledge on the mechanisms of lymphangiogenesis may help elucidate the pathophysiology of Gorham disease and lead to novel treatment targets. Here, we discuss our current understanding of Gorham disease, discuss established and emerging therapeutic strategies, and attempt to frame a treatment rationale.
Url:
DOI: 10.1002/pbc.24832
PubMed: 24214028
PubMed Central: 4123459
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: 003485
- to stream Pmc, to step Curation: 003484
- to stream Pmc, to step Checkpoint: 002108
- to stream Ncbi, to step Merge: 005F16
- to stream Ncbi, to step Curation: 005F16
- to stream Ncbi, to step Checkpoint: 005F16
- to stream Main, to step Merge: 003350
- to stream Main, to step Curation: 003344
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Novel molecular pathways in Gorham disease: Implications for treatment</title><author><name sortKey="Hagendoorn, Jeroen" sort="Hagendoorn, Jeroen" uniqKey="Hagendoorn J" first="Jeroen" last="Hagendoorn">Jeroen Hagendoorn</name></author><author><name sortKey="Yock, Torunn I" sort="Yock, Torunn I" uniqKey="Yock T" first="Torunn I." last="Yock">Torunn I. Yock</name></author><author><name sortKey="Rinkes, Inne H M Borel" sort="Rinkes, Inne H M Borel" uniqKey="Rinkes I" first="Inne H. M. Borel" last="Rinkes">Inne H. M. Borel Rinkes</name></author><author><name sortKey="Padera, Timothy P" sort="Padera, Timothy P" uniqKey="Padera T" first="Timothy P." last="Padera">Timothy P. Padera</name></author><author><name sortKey="Ebb, David H" sort="Ebb, David H" uniqKey="Ebb D" first="David H." last="Ebb">David H. Ebb</name></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">24214028</idno><idno type="pmc">4123459</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4123459</idno><idno type="RBID">PMC:4123459</idno><idno type="doi">10.1002/pbc.24832</idno><date when="2013">2013</date><idno type="wicri:Area/Pmc/Corpus">003485</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">003485</idno><idno type="wicri:Area/Pmc/Curation">003484</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">003484</idno><idno type="wicri:Area/Pmc/Checkpoint">002108</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">002108</idno><idno type="wicri:Area/Ncbi/Merge">005F16</idno><idno type="wicri:Area/Ncbi/Curation">005F16</idno><idno type="wicri:Area/Ncbi/Checkpoint">005F16</idno><idno type="wicri:doubleKey">1545-5009:2013:Hagendoorn J:novel:molecular:pathways</idno><idno type="wicri:Area/Main/Merge">003350</idno><idno type="wicri:Area/Main/Curation">003344</idno><idno type="wicri:Area/Main/Exploration">003344</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Novel molecular pathways in Gorham disease: Implications for treatment</title><author><name sortKey="Hagendoorn, Jeroen" sort="Hagendoorn, Jeroen" uniqKey="Hagendoorn J" first="Jeroen" last="Hagendoorn">Jeroen Hagendoorn</name></author><author><name sortKey="Yock, Torunn I" sort="Yock, Torunn I" uniqKey="Yock T" first="Torunn I." last="Yock">Torunn I. Yock</name></author><author><name sortKey="Rinkes, Inne H M Borel" sort="Rinkes, Inne H M Borel" uniqKey="Rinkes I" first="Inne H. M. Borel" last="Rinkes">Inne H. M. Borel Rinkes</name></author><author><name sortKey="Padera, Timothy P" sort="Padera, Timothy P" uniqKey="Padera T" first="Timothy P." last="Padera">Timothy P. Padera</name></author><author><name sortKey="Ebb, David H" sort="Ebb, David H" uniqKey="Ebb D" first="David H." last="Ebb">David H. Ebb</name></author></analytic><series><title level="j">Pediatric blood & cancer</title><idno type="ISSN">1545-5009</idno><idno type="eISSN">1545-5017</idno><imprint><date when="2013">2013</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p id="P1">Rapid advances in evidence-based treatment schedules are a hallmark of modern oncology. In rare neoplastic diseases, however, clinical expertise is hard to build and evidence based on randomized trials almost impossible to conduct. Gorham disease is a rare form of lymphatic proliferation accompanied by osteolysis, which usually occurs in young adults. Despite the fact that the clinical course of Gorham disease is often devastating and occasionally fatal, insights into its biological background are sparse and standardized treatment unavailable. Interestingly, recent knowledge on the mechanisms of lymphangiogenesis may help elucidate the pathophysiology of Gorham disease and lead to novel treatment targets. Here, we discuss our current understanding of Gorham disease, discuss established and emerging therapeutic strategies, and attempt to frame a treatment rationale.</p></div></front></TEI><affiliations><list></list><tree><noCountry><name sortKey="Ebb, David H" sort="Ebb, David H" uniqKey="Ebb D" first="David H." last="Ebb">David H. Ebb</name><name sortKey="Hagendoorn, Jeroen" sort="Hagendoorn, Jeroen" uniqKey="Hagendoorn J" first="Jeroen" last="Hagendoorn">Jeroen Hagendoorn</name><name sortKey="Padera, Timothy P" sort="Padera, Timothy P" uniqKey="Padera T" first="Timothy P." last="Padera">Timothy P. Padera</name><name sortKey="Rinkes, Inne H M Borel" sort="Rinkes, Inne H M Borel" uniqKey="Rinkes I" first="Inne H. M. Borel" last="Rinkes">Inne H. M. Borel Rinkes</name><name sortKey="Yock, Torunn I" sort="Yock, Torunn I" uniqKey="Yock T" first="Torunn I." last="Yock">Torunn I. Yock</name></noCountry></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003344 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003344 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= PMC:4123459
|texte= Novel molecular pathways in Gorham disease: Implications for treatment
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:24214028" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |